871657-49-7 Usage
Uses
Used in Pharmaceutical Industry:
3-ISOPROPOXY-AZETIDINE HYDROCHLORIDE is used as a building block in organic synthesis for the development of new drugs and medications. Its unique chemical structure allows for the creation of innovative pharmaceutical compounds that can address various medical conditions.
Used in Drug Discovery and Development:
3-ISOPROPOXY-AZETIDINE HYDROCHLORIDE is used as a research tool by chemists and researchers working in drug discovery and development. Its properties enable the exploration of new chemical pathways and the synthesis of novel compounds with potential therapeutic applications.
Used in Specialty Chemicals Production:
3-ISOPROPOXY-AZETIDINE HYDROCHLORIDE is used as a component in the production of specialty chemicals, where its unique properties can contribute to the development of advanced materials with specific characteristics and applications.
Used in Advanced Materials Industry:
3-ISOPROPOXY-AZETIDINE HYDROCHLORIDE is used in the development of advanced materials, where its chemical properties can enhance the performance of these materials in various applications, such as in electronics, coatings, or other high-tech industries.
Check Digit Verification of cas no
The CAS Registry Mumber 871657-49-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,7,1,6,5 and 7 respectively; the second part has 2 digits, 4 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 871657-49:
(8*8)+(7*7)+(6*1)+(5*6)+(4*5)+(3*7)+(2*4)+(1*9)=207
207 % 10 = 7
So 871657-49-7 is a valid CAS Registry Number.
871657-49-7Relevant academic research and scientific papers
HETROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES
-
Page/Page column 155, (2008/06/13)
Compounds of Formula (I) wherein: R1 is hydroxymethyl; R2 is selected from -C(O)NR4R5, SO2NR4R5, S(O)pR4 and HET-2; HET-1 is a 5- or 6-membered, optionally substituted C-linked heteroaryl ring; HET-2 is a 4-, 5- or 6-membered, C- or N-linked optionally substituted heterocyclyl ring; R3 is selected from halo, fluoromethyl, difluoromethyl, trifluoromethyl, methyl, methoxy and cyano; R4 is selected from for example hydrogen, optionally substituted (1-4C)alkyl and HET-2; R5 is hydrogen or (1-4C)alkyl; or R4 and R5 together with the nitrogen atom to which they are attached may form a heterocyclyl ring system as defined by HET-3; HET-3 is for example an optionally substituted N-linked, 4, 5 or 6 membered, saturated or partially unsaturated heterocyclyl ring; p is (independently at each occurrence) 0, 1 or 2; m is 0 or 1; n is 0, 1 or 2; provided that when m is 0, then n is 1 or 2; or a salt, pro drug or solvate thereof, are described. Their use as GLK activators, pharmaceutical compositions containing them, and processes for their preparation are also described.
